[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Universitario Dr. Jose E. Gonzalez\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,82,112,136,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100627670","phase-2-low-dose-epcoritamab-plus-gemox-in-rr-dlbcl-100627670",false,"NCT07451652","Low Dose Epcoritamab Plus GemOx in R\u002FR DLBCL","Low Dose Epcoritamab Plus Gemcitabine\u002FOxaliplatin in Treatment of Transplant Eligible Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Subjects with relapsed\u002Frefractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant\n* ECOG 0-2\n* Women of reproductive age who agree on getting a contraceptive method\n* Subjects who fulfill Lugano´s criteria for disease activity\n* Subjects who voluntarily accept to participate in this study\n\nExclusion Criteria:\n\n* Active bacterial, viral or fungal infection\n* Subjects who have already received an autologous o allogeneic stem cell transplantation\n* Subjects with other active neoplasias\n* Subjects with end-stage failure","ALL","18 Years","65 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","In this study, researchers are looking to determine whether Gemcitabine\u002FOxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed\u002Frefractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.",[27],"Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[29,30,31,32,33,34],"relapsed\u002Frefractory diffuse large B cell lymphoma","epcoritamab","GemOx","gemcitabine","oxaliplatin","autologous stem cell transplant","RECRUITING","2026-03-26",{"date":38,"type":39},"2026-04-01","ACTUAL",{"date":41,"type":39},"2026-03-17",{"date":43,"type":21},"2027-09",{"name":45,"class":46},"Hospital Universitario Dr. Jose E. Gonzalez","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100623850","phase-4-effects-of-semaglutide-on-clinical-outcomes-and-metabolic-inflammation-in-psoriasis-100623850","NCT07401992","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","SEMAPSO","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of randomization.\n* Clinical diagnosis of plaque psoriasis with Psoriasis Area and Severity Index (PASI) ≥3 and body surface area (BSA) ≥3%.\n* Body mass index (BMI) ≥25 kg\u002Fm², consistent with overweight or obesity.\n* Participants with or without type 2 diabetes mellitus.\n* Participants with diabetes must be on stable antidiabetic therapy (no changes in medication or dosage within the previous 3 months) and have adequate glycemic control, defined as HbA1c ≤9.0% at baseline.\n* No use of systemic psoriasis therapies (e.g., methotrexate, cyclosporine) for at least 8 weeks prior to randomization.\n* No use of biologic therapies for at least 3 months prior to randomization.\n\nExclusion Criteria:\n\n* Diagnosis of a non-plaque psoriasis subtype, including pustular, guttate, nail, inverse, psoriatic arthritis, or erythrodermic psoriasis.\n* Pregnancy or breastfeeding at the time of screening or enrollment.\n* Insulin-dependent diabetes mellitus or current use of sulfonylureas.\n* Active malignancy at the time of screening.\n* History of thyroid neoplasia.\n* Presence of autoimmune diseases.\n* Use of systemic therapies within 8 weeks prior to randomization.\n* Use of biologic therapies within 3 months prior to randomization.\n* Renal insufficiency.\n* Heart failure.\n* Hepatic insufficiency.\n* History of pancreatitis.\n* Current treatment with other GLP-1 receptor agonists.\n* History of inflammatory bowel disease.\n* Known allergy to starch.",{"count":57,"type":21},62,[59],"PHASE4","This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid\u002Fcalcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight\u002Fobesity and\u002For type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid\u002Fcalcipotriol or placebo plus topical corticosteroid\u002Fcalcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.",[62,63,64],"Psoriasis (PsO)","Obesity & Overweight","Diabetes Mellitus - Type 2",[66,67,68,69,70,71,72,73],"clinical trial","psoriasis","dermatology","semaglutide","GLP-1","obesity","overweight","diabetes","2026-02-03",{"date":76,"type":39},"2026-02-11",{"date":78,"type":39},"2026-01-15",{"date":80,"type":21},"2027-02-28",{"name":45,"class":46},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100596009","phase-2-efficacy-of-low-dose-venetoclax-with-itraconazole--tacl-for-rr-all-patients-100596009","NCT07039877","Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R\u002FR ALL Patients","Efficacy of Low-dose Venetoclax With Itraconazole + TACL in Patients With Relapsed\u002FRefractory Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* B-cell or T-cell acute lymphoblastic leukemia.\n* Philadelphia chromosome negative\n* Relapsed disease after any line of treatment, defined as detection of disease activity at any time after remission\n* Refractory disease after first-line treatment, defined as: more than 5% blasts after completion of induction\u002Fconsolidation by flow cytometry\n* Not having included venetoclax in any prior regimen.\n* No prior organ damage, defined as the absence of any serious, life-threatening disease prior to the start of treatment.\n* Performance status defined by the ECOG scale between 0 and 2.\n\nExclusion Criteria:\n\n* Isolated CNS relapse.\n* Performance status defined by ECOG scale between 3 and 4.\n* CTCAE-classified sensory or motor neuropathy of grade 3 or higher.\n* History of hypersensitivity or intolerance to the drugs included in the regimen.\n* Prior organ damage, defined as the presence of any serious, life-threatening illness prior to the start of treatment.","16 Years","45 Years",{"count":92,"type":21},12,[24],"Relapsed\u002Frefractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries. With such poor 5-year overall survival rates of 10%, the investigators need strategies that surpass the complete response rate achieved in this setting, which does not exceed 60% effectiveness with different regimens, and to eventually transfer patients to hematopoietic stem cell transplantation.\n\nIn this context, the investigators are studyng if the use of venetoclax, a BCL2 inhibitor, with the use of a cytochrome p450 inhibitor such as itraconazole, alongside the TACL chemotherapy regimen, which is based on the combination of asparaginase, dexamethasone, bortezomib, vincristine, and mitoxantrone.",[96,97,98],"Acute Lymphobkastic Leukemia","Acute Lymphoblastic Leukaemia Recurrent","Philadelphia Chromosome Negative ALL",[16,100,101,102,103],"relapsed ALL","Venetoclax","TACL","refractoy ALL","2025-09-29",{"date":106,"type":39},"2025-10-02",{"date":108,"type":39},"2025-01-02",{"date":110,"type":21},"2026-04-30",{"name":45,"class":46},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":47},"100585610","phase-2-efficacy-of-human-chorionic-gonadotropin-in-acute-gvhd-treatment-100585610","NCT06904599","Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment","Evaluation of Human Chorionic Gonadotropin for the Treatment of Acute Graft-versus-host Disease in Patients With Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Any gender.\n* Post-allogeneic transplantation status (haploidentical or identical) of hematopoietic cells.\n* Presenting recently onset aGVHD, grades 2 to 4, and requiring systemic steroid use as determined by the treating physician.\n* Have not received steroids (Prednisone ≥1 mg\u002Fkg\u002Fday or equivalent dose of another steroid) for more than 3 days in the last week.\n* Willing to participate in the study by signing informed consent.\n* If the subject is female and has the potential to procreate (a woman is considered fertile from menarche to postmenopausal stage or after undergoing a permanent contraceptive method), she agrees to use one of the following contraceptive methods from the start of the study and for 30 days after the protocol: oral hormonal contraception, intrauterine device, barrier methods (diaphragm, male or female condom, and foam, sponge, or spermicide film), or agrees to remain abstinent. Women who have been postmenopausal for more than a year, undergone hysterectomy, bilateral oophorectomy, or bilateral salpingectomy are not considered to have reproductive potential.\n* If the subject is male, he agrees to use one of the following contraceptive methods from the start of the study and for 30 days after the protocol: male condom, or remain abstinent.\n\nExclusion Criteria:\n\n* Arterial or venous thrombosis in the past 3 months.\n* History of thromboembolic disease requiring full-dose anticoagulation.\n* Diagnosis of active malignant disease.\n* Uncontrolled infection.\n* Chronic use of supplemental therapy with sex hormones (estrogen, progesterone, and\u002For testosterone).\n* Women with a positive pregnancy test at the time of the initial evaluation.\n* Women or men of reproductive age who are unwilling to take appropriate precautions to avoid an unwanted pregnancy from the start of the protocol until 30 days after the protocol.",{"count":120,"type":21},20,[24],"Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a second-line therapy is added, which is expensive and not easily accessible. The administration of human chorionic gonadotropin has shown therapeutic effectiveness in 50% of patients in reported clinical cases.",[124],"Acute Graft Versus Host Disease",[126,127],"Acute GVHD","human chorionic gonadotropin","2025-03-31",{"date":130,"type":39},"2025-04-03",{"date":132,"type":39},"2025-02-01",{"date":134,"type":21},"2026-01-31",{"name":45,"class":46},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":47},"100574368","phase-2-low-dose-teclistamab-in-newly-diagnosed-multiple-myeloma-patients-100574368","NCT06758375","Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients","Low-dose Teclistamab As Consolidation in the First-line Treatment of Patients with Newly Diagnosed Multiple Myeloma.","Inclusion Criteria:\n\n* ≥18 years of age.\n* Newly diagnosed multiple myeloma.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.\n* Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of contraception, such as a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomy partner.\n* Males: agree to use a highly effective contraceptive method, such as a male condom or vasectomy.\n\nExclusion Criteria:\n\n* History of previous treatment for MM.\n* Active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma.\n* Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or AL amyloidosis.\n* Severe active infection secondary to viruses, bacteria or fungi.\n* Pulmonary disease requiring supplemental oxygen.\n* History of allogeneic or autologous hematopoietic cell transplantation.\n* Vaccination with live attenuated virus in the 4 weeks prior to teclistamab administration.\n* Major surgery during the 2 weeks prior to the first dose or absence of complete recovery from surgery.\n* Presence of other concomitant malignancy.\n* Hepatitis B and C virus infection or human immunodeficiency virus (HIV) infection.\n* Cerebrovascular events or seizures in the last 6 months.\n* Congestive heart failure class III-IV according to NYHA (New York Heart Association Stage).\n* Acute myocardial infarction or history of coronary revascularization surgery in the last 6 months.\n* Women of childbearing age: active pregnancy prior to the first administration of treatment.",{"count":20,"type":21},[24],"This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.",[147],"Multiple Myeloma, Newly Diagnosed",[149,150,151,152],"Multiple myeloma","Teclistamab","Newly diagnosed multiple myeloma","Low-dose teclistamab","2025-03-19",{"date":155,"type":39},"2025-03-20",{"date":157,"type":39},"2025-03-03",{"date":159,"type":21},"2026-12-01",{"name":45,"class":46},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":47},"100584187","phase-2-efficacy-of-short-course-blinatumomab-for-mrd-erradication-in-b-all-100584187","NCT06886074","Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL","Efficacy of Short-course Blinatumomab in Patients With Detectable Measurable Residual Disease With Philadelphia Chromosome-negative B-cell Acute Lymphoblastyc Leukemia","Inclusion Criteria:\n\n* Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia\n* MRD detectable in complete response (above the limit of quantification according to FCM)\n* Performance status 0-2 on the ECOG scale\n* No prior organ damage\n* Having a potential related or unrelated donor\n\nExclusion Criteria:\n\n* Performance status on the ECOG scale \\>2\n* HCT-CI \\>3 points\n* Patients who do not wish to participate in clinical study.\n* Active central nervous system infiltration (CNS3)\n* Active extramedullary disease\n* Having previously received blinatumomab\n* Absence of related or unrelated donors","60 Years",{"count":170,"type":21},30,[24],"Detectable measurable residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) for overall survival (OS) and disease-free survival (DFS). Patients who are MRD positive and have no access to novel immunotherapies should receive an allogeneic hematopoietic stem cell transplantation (HSCT). Blinatumomab is considered a standard of care (SOC) for this group of patients, however, the ideal treatment dose for MRD is unknown as doses were adjusted from the relapsed\u002Frefractory setting. Preliminary data suggest short cycles of blinatumomab can also be effective in states of lower disease burden prior to transplant. Thus, the investigators are performing a phase 2 trial assessing 7 days of blinatumomab as a bridge to HSCT\n\nPrimary endpoint is assessing the MRD response following a short-course blinatumomab infusion in patients with B-ALL with complete response (CR) and have detectable MRD disease who are candidates for HSCT. Secondary endpoints include incidence of adverse events, OS, DFS, percentage of patients who receive HSCT, incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS)",[174,175],"Acute Lymphoblastic Leukemia","Measurable Residual Disease (MRD)",[177,178],"Blinatumomab","Measurable residual disease","2025-03-18",{"date":155,"type":39},{"date":108,"type":39},{"date":183,"type":21},"2027-06",{"name":45,"class":46},""]